• 1
    Gelboin HV. Benzo[alpha]pyrene metabolism, activation and carcinogenesis: role and regulation of mixed-function oxidases and related enzymes. Physiol Rev 1980;60: 110766.
  • 2
    Denissenko MF, Pao A, Tang M, Pfeifer GP. Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in P53. Science 1996;274: 4302.
  • 3
    Benhamou S, Sarasin A. 2000. Variability in nucleotide excision repair and cancer risk: a review. Mutat Res 2000;462: 14958.
  • 4
    Wei Q, Cheng L, Amos CI, Wang LE, Zhaozheng G, Hong WK, Spitz MR. Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk: a molecular epidemiologic study [In Process Citation]. J Natl Cancer Inst 2000;92: 176472.
  • 5
    Shen MR, Jones IM, Mohrenweiser H. Nonconservative amino acid substitution variants exist at polymorphic frequency in DNA repair genes in healthy humans. Cancer Res 1998;58: 6048.
  • 6
    Butkiewicz D, Rusin M, Enewold L, Shields PG, Chorazy M, Harris CC. Genetic polymorphisms in DNA repair genes and risk of lung cancer. Carcinogenesis 2001;22: 5937.
  • 7
    Divine KK, Gilliland FD, Crowell RE, Stidley CA, Bocklage TJ, Cook DL, Belinsky SA. The XRCC1 399 glutamine allele is a risk factor for adenocarcinoma of the lung. Mutat Res 2001;461: 2738.
  • 8
    Ratnasinghe D, Yao SX, Tangrea JA, Qiao YL, Andersen MR, Barrett MJ, Giffen CA, Erozen Y, Tockman MS, Taylor PP. Polymorphisms of the DNA repair gene XRCC1 and lung cancer risk. Cancer Epidemiol Biomarkers Prev 2001;10: 11923.
  • 9
    Spitz MR, Wu X, Wang Y, Shete S, Amos CI, Guo Z, Lei L, Mohrenweiser H, Wei Q. Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients. Cancer Res 2001;61: 13547.
  • 10
    Batty DP, Wood RD. Damage recognition in nucleotide excision repair of DNA. Gene 2000;241: 193204.
  • 11
    Caldecott KW, Aoufouchi S, Johnson P, Shall S. XRCC1 polypeptide interacts with DNA polymerase beta and possibly poly (ADP-ribose) polymerase, and DNA ligase III is a novel molecular ‘nick- sensor’ in vitro. Nucleic Acids Res 1996;24: 438794.
  • 12
    Lunn RM, Helzlsouer KJ, Parshad R, Umbach DM, Harris EL, Sanford KK, Bell DA. XPD polymorphisms: effects on DNA repair proficiency. Carcinogenesis 2000;21: 5515.
  • 13
    Pastorelli R, Guanci M, Cerri A, Negri E, La Vecchia C, Fumagalli F, Mezzetti M, Cappelli R, Panigalli T, Fanelli R, Airoldi L. Impact of inherited polymorphisms in glutathione S-transferase M1, microsomal epoxide hydrolase, cytochrome P450 enzymes on DNA, and blood protein adducts of benzo(a)pyrene-diolepoxide. Cancer Epidemiol Biomarkers Prev 1998;7: 7039.
  • 14
    Vineis P, Perera F. DNA adducts as markers of exposure to carcinogens and risk of cancer [In Process Citation]. Int J Cancer 2000;88: 3258.
  • 15
    Braithwaite E, Wu X, Wang Z. Repair of DNA lesions induced by polycyclic aromatic hydrocarbons in human cell-free extracts: involvement of two excision repair mechanisms in vitro. Carcinogenesis 1998;19: 123946.
  • 16
    Casale GP, Singhal M, Bhattacharya S, Ramanathan R, Roberts KP, Barbacci DC, Zhao J, Jankowiak R, Gross ML, Cavalieri EL, Small GJ, Rennard SI, et al. Detection and quantification of depurinated benzo[a]pyrene-adducted DNA bases in the urine of cigarette smokers and women exposed to household coal smoke. Chem Res Toxicol 2001;14: 192201.
  • 17
    Lunn RM, Langlois RG, Hsieh LL, Thompson CL, Bell DA. XRCC1 polymorphisms: effects on aflatoxin B1-DNA adducts and glycophorin A variant frequency. Cancer Res 1999;59: 255761.
  • 18
    David-Beabes GL, Lunn RM, London SJ. No association between the XPD (Lys751G1n) polymorphism or the XRCC3 (Thr241Met) polymorphism and lung cancer risk. Cancer Epidemiol Biomarkers Prev 2001;10: 9112.
  • 19
    Strange RC, Fryer AA. The glutathione S-transferases: influence of polymorphism on cancer susceptibility. no. 148. Lyon: IARC, 1999. 23149.
  • 20
    Shields PG, Bowman ED, Harrington AM, Doan VT, Weston A. Polycyclic aromatic hydrocarbon-DNA adducts in human lung and cancer susceptibility genes. Cancer Res 1993;53: 348692.
  • 21
    Butkiewicz D, Grzybowska E, Phillips DH, Hemminki K, Chorazy M. Polymorphisms of the GSTP1 and GSTM1 genes and PAH-DNA adducts in human mononuclear white blood cells. Environ Mol Mutagen 2000;35: 99105.
  • 22
    Rothman N, Shields PG, Poirier MC, Harrington AM, Ford DP, Strickland PT. The impact of glutathione s-transferase M1 and cytochrome P450 1A1 genotypes on white-blood-cell polycyclic aromatic hydrocarbon-DNA adduct levels in humans. Mol Carcinog 1995;14: 638.
  • 23
    Tang DL, Rundle A, Warburton D, Santella RM, Tsai WY, Chiamprasert S, Hsu YZ, Perera FP. Associations between both genetic and environmental biomarkers and lung cancer: evidence of a greater risk of lung cancer in women smokers. Carcinogenesis 1998;19: 194953.
  • 24
    Stern MC, Umbach DM, van Gils CH, Lunn RM, Taylor JA. DNA repair gene XRCC1 polymorphisms, smoking, and bladder cancer risk. Cancer Epidemiol Biomarkers Prev 2001;10: 12531.
  • 25
    Tang D, Phillips DH, Stampfer M, Tang D, Phillips DH, Stampfer M, Mooney LA, Hsu Y, Cho S, Tsai WY, Ma J, Cole KJ, She MN, Perera FP. Association between carcinogen-DNA adducts in white blood cells and lung cancer risk in the physicians health study. Cancer Res 2001;61: 670812.
  • 26
    Duell EJ, Wiencke JK, Cheng TJ, Varkonyi Z, Zuo ZF, Ashok TD, Mark EJ, Wain JC, Christiani DC, Kelsey KT. Polymorphisms in the DNA repair genes XRCC1 and ERCC2 and biomarkers of DNA damage in human blood mononuclear cells [published erratum appears in Carcinogenesis 2000 Jul;21(7):1457]. Carcinogenesis 2000;21: 96571.
  • 27
    Palli D, Russo A, Masala G, Saieva C, Guarrera S, Carturan S, Munnia A, Matullo G, Peluso M. DNA adduct levels and DNA repair polymorphisms in traffic-exposed workers and a general population sample. Int J Cancer 2001;94: 1217.
  • 28
    Matullo G, Guarrera S, Carturan S, Peluso M, Malaveille C, Davico L, Piazza A, Vineis P. DNA repair gene polymorphisms, bulky DNA adducts in white blood cells and bladder cancer in a case-control study. Int J Cancer 2001;92: 5627.
  • 29
    Matullo G, Palli D, Peluso M, Guarrera S, Carturan S, Celentano E, Krogh V, Munnia A, Tumino R, Polidoro S, Piazza A, Vineis P. XRCC1, XRCC3, XPD gene polymorphisms, smoking and (32)P-DNA adducts in a sample of healthy subjects. Carcinogenesis 2001;22: 143745.
  • 30
    Pero RW, Johnson DB, Miller DG, Zang E, Markowitz M, Doyle GA, Lund-Pero M, Salford L, Sordillo P, Raskin N, et al. Adenosine diphosphate ribosyl transferase responses to a standardized dose of hydrogen peroxide in the mononuclear leukocytes of patients with a diagnosis of cancer. Carcinogenesis 1989;10: 165764.
  • 31
    Berwick M, Vineis P. Markers of DNA repair and susceptibility to cancer in humans: an epidemiologic review. J Natl Cancer Inst 2000;92: 87497.
  • 32
    Rajaee-Behbahani N, Schmezer P, Risch A, Rittegen W, Kayser KW, Dienemann H, Schultz V, Drings P, Thiel S, Bartsch H. Altered DNA repair capacity and bleomycin sensitivity as risk markers for non-small cell lung cancer. Int J Cancer 2001;95: 8691.
  • 33
    Seker H, Butkiewicz D, Bowman ED, Rusin M, Hedayati M, Grossman L, Harris CC. Functional significance of xpd polymorphic variants: attenuated apoptosis in human lymphoblastoid cells with the xpd 312 asp/asp genotype. Cancer Res 2001;61: 74304.
  • 34
    The World Health Organization histological typing of lung tumours. 2nd ed. Am J Clin Pathol 1982; 77: 12336.